Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT

Y Intercept Hong Kong Ltd cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 91.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 78,735 shares of the biotechnology company’s stock after selling 791,446 shares during the quarter. Y Intercept Hong Kong Ltd owned approximately 0.08% of Sarepta Therapeutics worth $1,517,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. AQR Capital Management LLC grew its stake in Sarepta Therapeutics by 214.2% in the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after purchasing an additional 3,671 shares during the period. Great Lakes Advisors LLC purchased a new position in shares of Sarepta Therapeutics in the 1st quarter worth about $224,000. Public Employees Retirement System of Ohio boosted its holdings in shares of Sarepta Therapeutics by 2.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock worth $492,000 after buying an additional 607 shares during the last quarter. Janney Montgomery Scott LLC grew its position in Sarepta Therapeutics by 123.5% during the second quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 15,882 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Sarepta Therapeutics by 25.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $69,000 after buying an additional 819 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 4.2%

SRPT stock opened at $20.34 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The company’s 50 day moving average is $21.56 and its 200 day moving average is $19.89. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -6.76, a price-to-earnings-growth ratio of 0.52 and a beta of 0.48. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $120.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The company had revenue of $399.36 million during the quarter, compared to analysts’ expectations of $331.51 million. During the same quarter last year, the firm posted $0.62 earnings per share. The firm’s revenue was down 14.5% on a year-over-year basis. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares in the company, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on SRPT shares. Bank of America increased their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a research report on Wednesday, October 22nd. Wall Street Zen downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Royal Bank Of Canada raised their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday. Finally, Guggenheim cut their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $33.84.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.